Spots Global Cancer Trial Database for systemic therapy
Every month we try and update this database with for systemic therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs | NCT06160167 | Multiple Myelom... | IMiD treatment No IMiD treatme... Systemic therap... | 18 Years - | Bristol-Myers Squibb | |
| Integrated Patient Avatars for Guiding Systemic Therapy Treatments in Metastatic Breast Cancer Patients | NCT04608357 | Breast Cancer Breast Neoplasm... Metastatic Brea... Cancer, Breast | Needle Core Bio... | 18 Years - | Sunnybrook Health Sciences Centre | |
| Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs | NCT06160167 | Multiple Myelom... | IMiD treatment No IMiD treatme... Systemic therap... | 18 Years - | Bristol-Myers Squibb | |
| Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors | NCT01755182 | Neuroendocrine ... | approved pharma... TAE | 18 Years - 80 Years | National Cancer Institute, Naples | |
| Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer | NCT04614103 | Metastatic Non ... | LN-145 LN-145 | 18 Years - 70 Years | Iovance Biotherapeutics, Inc. | |
| A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | NCT05361174 | Unresectable Me... Metastatic Mela... Stage III Non-s... Stage IV Non-sm... | IOV-4001 | 18 Years - | Iovance Biotherapeutics, Inc. | |
| Evaluating the CAREchart@Home™ Program for Enhancing After-hours Cancer Care | NCT04232709 | Cancer | Shared electron... | 18 Years - 100 Years | Women's College Hospital | |
| Predicting Response to Systemic Therapies for Hepatocellular Carcinoma(HCC) | NCT05543304 | Hepatocellular ... Effect of Drug | radiological ev... | 18 Years - 80 Years | First Affiliated Hospital of Wenzhou Medical University | |
| Predicting Response to Systemic Therapies for Hepatocellular Carcinoma(HCC) | NCT05543304 | Hepatocellular ... Effect of Drug | radiological ev... | 18 Years - 80 Years | First Affiliated Hospital of Wenzhou Medical University | |
| Multicenter Tissue Registry in Melanoma | NCT05750511 | Metastatic Mela... | molecular tissu... | 18 Years - | Dermatologic Cooperative Oncology Group | |
| TERPS Trial for de Novo Oligometastic Prostate Cancer | NCT05223803 | Prostate Cancer Oligometastatic... | Prostate radiat... Systemic Therap... Stereotactic ab... | 18 Years - | University of Maryland, Baltimore | |
| Compare the Efficacy of Surgery Combined With Systemic Therapy and Pure Systemic Therapy in Breast Cancer Patients | NCT04199520 | Stage IV Breast... | surgery combine... systemic therap... | 18 Years - 70 Years | Henan Cancer Hospital | |
| VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy | NCT05920343 | Venous Thromboe... Urologic Cancer | Rivaroxaban 10 ... Placebo control | 18 Years - | Ottawa Hospital Research Institute | |
| Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas | NCT03149120 | Soft Tissue Sar... | Nivolumab Pazopanib | 18 Years - 100 Years | NYU Langone Health | |
| AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas | NCT06340737 | Follicular Lymp... Mantle Cell Lym... Hairy Cell Leuk... Lymphoplasmacyt... Burkitt Lymphom... Marginal Zone L... Waldenstrom Mac... | CD22CART Infusi... | 18 Years - | Stanford University | |
| Effect of Sarcopenia on Hepatocellular Carcinoma(HCC) After Systemic Therapies | NCT05448222 | Hepatocellular ... Sarcopenia | Diagnostic Test... | 18 Years - 80 Years | First Affiliated Hospital of Wenzhou Medical University | |
| A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas | NCT03991559 | Solid Tumor Lymphoma | Manganese Chlor... Anti-PD-1 antib... Systemic therap... | 18 Years - 80 Years | Chinese PLA General Hospital | |
| Effect of Sarcopenia on Hepatocellular Carcinoma(HCC) After Systemic Therapies | NCT05448222 | Hepatocellular ... Sarcopenia | Diagnostic Test... | 18 Years - 80 Years | First Affiliated Hospital of Wenzhou Medical University | |
| Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study | NCT05863351 | Metastatic Rena... Stage IV Renal ... | Computed Tomogr... Magnetic Resona... Questionnaire A... Stereotactic Ab... Systemic Therap... | 18 Years - | Eastern Cooperative Oncology Group | |
| Classified Treatment Strategy for De-novo Metastatic Breast Cancer After Systemic Adjuvant Therapy | NCT05285332 | Breast Neoplasm... Treatment Metastatic Brea... Survival | surgical treatm... surgical treatm... Systemic therap... | 18 Years - 75 Years | Changhai Hospital | |
| SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) | NCT01352520 | CD-30 Positive ... Lymphoma, Prima... Lymphomatoid Pa... Mycosis Fungoid... Skin Lymphoma Cutaneous Lymph... Lymphoma Hematologic Dis... | SGN-35 | 18 Years - | M.D. Anderson Cancer Center | |
| Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs | NCT06160167 | Multiple Myelom... | IMiD treatment No IMiD treatme... Systemic therap... | 18 Years - | Bristol-Myers Squibb | |
| Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma | NCT06254248 | Liver Transplan... Hepatocellular ... Systemic Treatm... | Systemic therap... | 18 Years - 90 Years | Assistance Publique - Hôpitaux de Paris | |
| Survival Benefit of Primary Tumour Resection Compared to Systemic Therapy Alone in Stage IV Colorectal Cancer Patients | NCT06326619 | Colorectal Canc... Neoadjuvant Sys... | Primary tumor r... Systemic Therap... | - | Medizinische Hochschule Brandenburg Theodor Fontane | |
| TERPS Trial for de Novo Oligometastic Prostate Cancer | NCT05223803 | Prostate Cancer Oligometastatic... | Prostate radiat... Systemic Therap... Stereotactic ab... | 18 Years - | University of Maryland, Baltimore | |
| Predicting Response to Systemic Therapies for Hepatocellular Carcinoma(HCC) | NCT05543304 | Hepatocellular ... Effect of Drug | radiological ev... | 18 Years - 80 Years | First Affiliated Hospital of Wenzhou Medical University | |
| Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy | NCT06422247 | Peripheral T-ce... | Systemic therap... | 18 Years - | Bristol-Myers Squibb | |
| VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy | NCT05920343 | Venous Thromboe... Urologic Cancer | Rivaroxaban 10 ... Placebo control | 18 Years - | Ottawa Hospital Research Institute | |
| Predicting Response to Systemic Therapies for Hepatocellular Carcinoma(HCC) | NCT05543304 | Hepatocellular ... Effect of Drug | radiological ev... | 18 Years - 80 Years | First Affiliated Hospital of Wenzhou Medical University | |
| Local Therapy for Oligorecurrent and Oligometastatic Esophageal Squamous Cell Carcinoma | NCT03904927 | Oligorecurrent ... | Radiation, Surg... Systemic therap... | 18 Years - | Fudan University | |
| Integrated Patient Avatars for Guiding Systemic Therapy Treatments in Metastatic Breast Cancer Patients | NCT04608357 | Breast Cancer Breast Neoplasm... Metastatic Brea... Cancer, Breast | Needle Core Bio... | 18 Years - | Sunnybrook Health Sciences Centre | |
| The Efficacy and Safety of HIPEC Combined With PD-1 and SOX Chemotherapy for the Translational Treatment of GC or EGJC With PM | NCT06427252 | Gastric Cancer,... | HIPEC Systemic therap... | 18 Years - 75 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy | NCT05315687 | Anatomic Stage ... Metastatic Brea... Metastatic Carc... Prognostic Stag... | Y-90 SIR-Sphere... Yttrium-90 Micr... Systemic Therap... | 18 Years - | Emory University | |
| Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer | NCT04031378 | Metastatic Pros... Prostate Adenoc... | Single Dose Rad... Single Dose Rad... | 18 Years - | Fundacao Champalimaud | |
| Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study | NCT05863351 | Metastatic Rena... Stage IV Renal ... | Computed Tomogr... Magnetic Resona... Questionnaire A... Stereotactic Ab... Systemic Therap... | 18 Years - | Eastern Cooperative Oncology Group | |
| Bone Metastasis and Surgery in Breast Cancer | NCT02125630 | Breast Cancer Surgery | Surgery Systemic therap... | 20 Years - 80 Years | Federation of Breast Diseases Societies | |
| Detecting the Impact of Statin Therapy On Lowering Risk of Venous Thrombo-Embolic Events (DISOLVE) | NCT01524653 | Venous Thromboe... Deep Vein Throm... Neoplasms | Rosuvastatin Placebo | 18 Years - | University of Vermont | |
| Study of Palliative Radiation Therapy vs. no Palliative Radiation Therapy for Patients With High Risk Bone Metastases That Are Not Causing Significant Pain | NCT03523351 | Metastatic Soli... | Radiation Thera... Systemic Therap... | 18 Years - | Memorial Sloan Kettering Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
